Skip to main content
Two women and two men laughing

How can the KISQALI dose be adjusted to help manage adverse reactions? 

For patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), the once-daily KISQALI® (ribociclib) dose can be reduced from 600 mg (3 x 200-mg tablets) orally to 400 mg (2 x 200-mg tablets) to one 200-mg tablet, as needed, to help manage adverse reactions. Review the clinical guidance below for KISQALI dose adjustments in mBC.1
Reference: 1. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp.